Tuesday, January 27, 2026 1/27/2026

Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant

Award Number: P50CA240243
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/03/2020
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant - Project Summary (Overall) The Overall section of this Ovarian Cancer SPORE application describes the Background, Specific Aims, Innovation, and Research Plan of the three projects and four cores. We emphasize intra- SPORE collaborations and development of clinical trials with companion biomarkers. Through this SPORE application, we have tried to address several of the most urgent questions in ovarian cancer therapy. First, PARP inhibitors are a new and essential feature of high grade serous ovarian cancer (HGSC) therapy, but many patients eventually have cancer progression on these agents. Accordingly, in Project 1, we have designed clinical trials with drug combinations and correlative studies which will allow us to systematically extend the use of PARP inhibitors. Second, we recognize the emerging impact of immunotherapy on solid tumor treatment. Thus, in Project 2, we have designed a novel vaccine trial for ovarian cancer patients. Third, HGSC patients with primary refractory disease or those patients with recurrence whose cancer harbor underlying RAS mutations such as low grade serous or mucinous cancers pose a particularly difficult clinical problem. Accordingly, in Project 3, we will explore novel non-platinum drug combinations, such as the combination of a BCL inhibitor and a MEK inhibitor, and will examine predictive biomarkers and tumor responses evident in the extracellular activity. The Specific Aims of this DF/HCC ovarian cancer SPORE are as follows: Aim 1 (Project 1): ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOC); Aim 2 (Project 2): Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancer; Aim 3 (Project 3): Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$163,942 )
2026	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Centers Support Grants	000	5	1/6/2026	NON-COMPETING CONTINUATION	-$163,942
														Subtotal = -$163,942

Issue Date FY: 2024 ( Subtotal = $2,309,363 )
2024	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Centers Support Grants	001	5	9/11/2024	NON-COMPETING CONTINUATION	$2,309,363
2024	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Centers Support Grants	000	4	10/20/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,309,363

Issue Date FY: 2023 ( Subtotal = $2,245,572 )
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	4	7/28/2023	NON-COMPETING CONTINUATION	$2,245,572
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Centers Support Grants	002	4	9/14/2023	NON-COMPETING CONTINUATION	$0
2023	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	3	4/17/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,245,572

Issue Date FY: 2022 ( Subtotal = $2,156,021 )
2022	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	002	3	9/21/2022	NON-COMPETING CONTINUATION	$48,466
2022	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	3	8/15/2022	NON-COMPETING CONTINUATION	$2,107,555
2022	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	2	6/17/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,156,021

Issue Date FY: 2021 ( Subtotal = $2,264,107 )
2021	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	2	8/13/2021	NON-COMPETING CONTINUATION	$2,264,107
														Subtotal = $2,264,107

Issue Date FY: 2020 ( Subtotal = $2,483,069 )
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	001	1	8/21/2020	NEW	$0
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Centers Support Grants	000	1	8/3/2020	NEW	$2,483,069
														Subtotal = $2,483,069

Grand Total All Awards = $11,294,190

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant

Award Number: P50CA240243

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/03/2020

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer